White Nicholas J, Mehra Somya, Watson James A
Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, 10400, Thailand.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, OX3 7LG, UK.
Malar J. 2025 May 26;24(1):166. doi: 10.1186/s12936-025-05399-2.
Countries in the Greater Mekong sub-region (GMS) have been encouraged to deploy mass chloroquine treatments given monthly for four months to reduce the burden of vivax malaria. This paper summarizes briefly current knowledge on Plasmodium vivax epidemiology, the biology of vivax relapse and previous experience using dihydroartemisinin-piperaquine mass treatments in the GMS to show why this approach would be extremely cost-ineffective. Around 800 full treatment courses in 200 people would be needed to prevent one symptomatic case. Mass chloroquine treatment will contribute little or nothing to the elimination of vivax malaria in this area.
大湄公河次区域（GMS）的各国已受到鼓励，采用每月进行一次、为期四个月的大规模氯喹治疗，以减轻间日疟原虫疟疾的负担。本文简要总结了目前关于间日疟原虫流行病学、间日疟复发生物学的知识，以及此前在大湄公河次区域使用双氢青蒿素-哌喹大规模治疗的经验，以说明为何这种方法在成本效益上极其低下。预防一例有症状病例大约需要为200人提供800个完整疗程的治疗。大规模氯喹治疗对该地区消除间日疟原虫疟疾几乎没有作用。
